Mortality: all causes · healthy women, aged 35 to 60, and men, aged 45 to 60, living in France
Vitamins A, C, E + selenium + zinc showed no clear difference in mortality: all causes compared with placebo (high certainty).
1 finding from 1 review
Mortality: lung cancer · healthy women, aged 35 to 60, and men, aged 45 to 60, living in France
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality: all cancers · healthy women, aged 35 to 60, and men, aged 45 to 60, living in France
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Cancer mortality in trials using vitamin D3 (cholecalciferol) ( · adults
The intervention probably leads to lower cancer mortality in trials using vitamin D3 (cholecalciferol) ( (moderate certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality in trials using vitamin D3 (cholecalciferol) ( · adults
The intervention probably leads to lower all‐cause mortality in trials using vitamin D3 (cholecalciferol) ( (moderate certainty).
1 finding from 1 review
Intervention not reported
Cardiovascular mortality in trials using vitamin D3 (cholecalciferol) ( · adults
The intervention showed no clear difference in cardiovascular mortality in trials using vitamin D3… (low certainty).
1 finding from 1 review
All‐cause mortality · Partcipants with bladder cancer undergoing radical cystectomy (male n = 314, female n = 87; age (interquartile range) 59 to 74)Country:…
Oral nutritional supplements showed no clear difference in mortality compared with multivitamin and mineral supplement (low certainty).
1 finding from 1 review
Mortality within the longest · patients with vitamin K antagonist‐induced bleeding requiring acute intervention
It is very uncertain whether prothrombin complex concentrate changes overall mortality ‐ longest compared with any comparator (very low certainty).
1 finding from 1 review
Intervention not reported
Mortality · children and adults with CF
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Mortality · patients with venous thromboembolism
The intervention showed no clear difference in mortality (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality · children with measles
The intervention showed no clear difference in mortality (moderate certainty).
1 finding from 1 review
All‐cause Mortality events in TKR combined doses · patients with prevention of venous thromboembolism following total hip or knee replacement
Direct thrombin inhibitors showed no clear difference in all‐cause Mortality events in TKR combined doses compared with vitamin K antagonists (low certainty).
1 finding from 1 review
All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether aspirin (ASA) changes all‐cause mortality compared with vitamin K antagonist (VKA) (very low certainty).
2 findings from 1 review
All‐cause mortality · people with cancer with VTE receiving secondary prophylaxis
Idraparinux secondary prophylaxis showed no clear difference in all‐cause mortality compared with vitamin K antagonist secondary prophylaxis (moderate certainty).
1 finding from 1 review
All‐cause mortality · patients with active cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis showed no clear difference in all‐cause mortality compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
Mortality due to any cause · children with sickle cell anaemia and microalbuminuria
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality (time‐to‐event) · patients with cancer with venous thromboembolism
Low molecular weight heparin secondary prophylaxis showed no clear difference in all‐cause mortality (time‐to‐event) compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
All‐cause mortality (up to 3 months) · people with cancer with thrombosis prophylaxis and central venous catheters
Low‐molecular‐weight heparin (LMWH) showed no clear difference in all‐cause mortality (up to 3 months) compared with vitamin K antagonist (VKA) (low certainty).
1 finding from 1 review
Intervention not reported
Maternal mortality · Pregnant women
1 finding from 1 review
Intervention not reported
All‐cause mortality
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found